Most significantly, the association of misfolded and dysfunctional SOD1 protein with dopaminergic neuron loss in Parkinson's disease suggests that many of the therapies currently being trialled for their ability to influence misfolded mutant SOD1 biochemistry in SOD1‐linked familial ALS (Table 3) may also constitute novel disease‐modifying treatments for Parkinson's disease. Here, SOD1 is linked to amyotrophic lateral sclerosis.